“Tamil Nadu bans Coldrif cough syrup after child deaths in 2025, taking swift action to protect public health and ensure medicine safety for children.”
In a decisive public health move, the Tamil Nadu Food Safety and Drug Administration (TN-FSDA) has banned the sale of the cough syrup ‘Coldrif’ following the deaths of 11 children in Madhya Pradesh and Rajasthan. The ban came into effect from October 1, 2025, with the state ordering the immediate removal of the product from the market to prevent further casualties.
Tragic Incidents Prompt Action
The deaths, suspected to be linked to Coldrif, prompted inspections at the manufacturing facility in Sunguvarchathram, Kancheepuram district. Samples from the facility have been collected for rigorous testing to detect the presence of Diethylene Glycol (DEG) — a highly toxic chemical sometimes found as a contaminant in medicines. This tragic incident has not only raised alarms within Tamil Nadu but has also become a matter of national concern.
The syrup, manufactured by a Chennai-based pharmaceutical company, is distributed across Rajasthan, Madhya Pradesh, and Puducherry. Reports suggest that the syrup was widely used, especially for young children, which heightens the urgency of the matter and public outrage.
Union Health Ministry Advisory
In response to the crisis, the Union Health Ministry has issued a directive to all states and Union Territories advising against prescribing cough and cold syrups to children under two years of age. This precautionary step aims to prevent further tragedies while investigations are underway, marking one of the most significant public health advisories in recent times.
Government Measures
Tamil Nadu bans Coldrif cough syrup after child deaths has ordered an immediate halt to production at the implicated pharmaceutical facility pending lab reports. The FSDA is closely monitoring the situation and has vowed to enforce stringent quality checks before approving the resumption of production. Authorities are also reviewing manufacturing licenses for similar products to ensure compliance with safety standards.
Public Health Implications
This incident raises serious concerns about drug manufacturing standards and quality control in India. Medical experts and consumer safety advocates have called for stricter regulatory frameworks and regular audits of pharmaceutical companies, especially those producing medicines for children.
“Medicines for children should be held to the highest safety standards. This tragedy highlights systemic gaps in oversight that need urgent addressing,” said Dr. R. Mehta, a public health specialist.
Way Forward
The Tamil Nadu ban on Coldrif serves as a strong warning for both manufacturers and regulators. It underscores the need for stringent quality control measures, better inspection mechanisms, and vigilant monitoring to protect public health, particularly vulnerable populations such as children. This case may also push for legislative reforms to strengthen pharmaceutical safety laws.
Tamil Nadu bans Coldrif cough syrup after child deaths: Conclusion
The Coldrif case is a tragic reminder that pharmaceutical safety cannot be compromised. Tamil Nadu’s swift action reflects a commitment to public health, but it also calls for long-term reforms to prevent similar incidents in the future. The tragedy emphasizes the importance of safeguarding children’s health through stricter regulation and proactive oversight.
FOR MORE BLOGS – beyondthepunchlines.com
Author: Team BTP
Add to favorites
